GLP-1 receptor agonists, originally developed for type 2 diabetes, now show robust clinical evidence for treating obesity, heart failure with preserved ejection fraction, chronic kidney disease, and metabolic liver disease.
Multiple organ systems, one drug classGLP-1 receptor agonists now have clinical trial evidence supporting benefits across at least four major disease categories beyond diabetes — obesity, heart failure, chronic kidney disease, and metabolic liver disease — making them one of the most versatile drug classes in modern medicine.
What the researchers found
Robust clinical trial data now supports GLP-1 RA efficacy across multiple conditions beyond diabetes: significant weight loss in obesity, improved cardiovascular outcomes, preserved renal function in chronic kidney disease, and benefits in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Heart failure with preserved ejection fraction (HFpEF) has emerged as a particularly promising indication.
Additional trials are underway to strengthen the evidence base for these newer indications. The review also notes that innovations including oral GLP-1 formulations and combination therapies (such as dual GLP-1/GIP agonists) may expand access and improve treatment adherence.
Why it matters
GLP-1 receptor agonists are arguably the most impactful new drug class in medicine today. Understanding the full scope of their potential applications is essential for clinicians across multiple specialties — not just endocrinologists. This review provides a comprehensive roadmap of where the evidence stands for each emerging indication, helping guide clinical decision-making as guidelines evolve rapidly.
How the study worked
This is a narrative review synthesizing clinical trial data and emerging evidence on GLP-1 receptor agonist use across cardiometabolic diseases. The authors reviewed major clinical trials, guideline updates, and ongoing research to assess the current state and future direction of GLP-1 RA therapeutics beyond their original diabetes indication.
What this study cannot tell us
As a narrative review, the paper is subject to selection bias in the studies chosen for discussion. Many of the emerging indications are still supported by a limited number of trials, and long-term outcomes data is still accumulating. The review acknowledges significant practical barriers including cost, access, and adherence that limit real-world implementation. Head-to-head comparisons between different GLP-1 RAs for non-diabetes indications are largely lacking.
How to read the evidence
This is a narrative review that synthesizes evidence from multiple randomized controlled trials and clinical studies. While individual trials cited include high-quality RCTs, the review itself does not perform systematic analysis or meta-analysis, and the strength of evidence varies across the different indications discussed.
When this study was published
Published in 2026, this is a highly current review reflecting the latest clinical trial data and guideline updates for GLP-1 receptor agonists across emerging indications.
The bigger picture
The GLP-1 RA story represents one of the most remarkable expansions of a drug class in modern medicine — from a diabetes drug to a potential treatment for heart failure, kidney disease, liver disease, and possibly neurodegenerative diseases and addiction. This review captures a pivotal moment in that expansion, as the field transitions from early trials to clinical guideline integration across multiple medical specialties.
Questions still open
- Which emerging GLP-1 RA indications will gain formal FDA approval first — heart failure, kidney disease, or liver disease?
- Will oral GLP-1 formulations achieve comparable efficacy to injectable versions across all these indications?
- How will healthcare systems manage the cost burden of prescribing GLP-1 drugs for an exponentially larger patient population beyond diabetes?
Common questions
What conditions beyond diabetes can GLP-1 drugs now treat?
Why do GLP-1 drugs work for so many different conditions?
Read the original research
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.
Reviews in cardiovascular medicine, 27(1), 44528
Citation
West, Lucianne; Patolia, Harsh; Chapman, Brittany; Laffin, Luke; Vest, Amanda R; Sauer, Andrew J; Martyn, Trejeeve. (2026). Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.. Reviews in cardiovascular medicine, 27(1), 44528. https://doi.org/10.31083/RCM44528